NEW YORK, June 4, 2020 /PRNewswire-HISPANIC PR WIRE/ — The following is being issued by Prime Clerk LLC.

In light of the ongoing COVID-19 pandemic, the U.S. Bankruptcy Court for the Southern District of New York has granted a 30-day extension of the deadline to file a claim against Purdue Pharma L.P.,¹ including claims related to Purdue prescription opioids, like OxyContin.² The new deadline or “bar date” is Thursday, July 30, 2020, at 5:00 p.m. (Prevailing Eastern Time).

If someone thinks they have suffered harm from Purdue or its prescription opioids, they have the right to file a claim, even if they also have received reimbursement from insurance, but they may lose the right to do so if they do not file a claim by the extended bar date.

A “claim” means a right to seek payment or other compensation.  Examples of claims that may be filed include death, addiction or dependence, lost wages, loss of spousal relationship benefit for things like child-rearing, enjoyment of life, etc., or Neonatal Abstinence Syndrome (sometimes referred to as “NAS”), among others.

Claims can be filed by the claimant, a lawyer, a legal guardian, survivors, or relatives of people who have died or are disabled.  You do not need an attorney to file a proof of claim for you.

All Personal Injury Claimant Proof of Claim Forms and any supporting documentation submitted with those forms will be kept highly confidential and will not be made available to the public.  You do not need to submit supporting documentation in order to file a claim, though you may be required to do so at a later time.

Additionally, partnerships, corporations, joint ventures, trusts, governmental units, and Native American Tribes may also file a proof of claim against Purdue.

Go to www.PurduePharmaClaims.com to find a complete list of instructions on how to file a claim.  You will also find a list of the opioids produced, marketed or sold by Purdue.  You can also request a claim form by mail, email or phone:

Purdue Pharma Claims Processing Center
c/o Prime Clerk LLC
850 Third Avenue, Ste. 412, Brooklyn, NY 11232
Email: [email protected]
Phone: 1.844.217.0912

¹ Purdue Pharma LLC is a U.S. limited partnership, its general partner and its subsidiaries, including Imbrium Therapeutics L.P., Adlon Therapeutics L.P., Greenfield BioVentures L.P., Avrio Health L.P., Rhodes Technologies, and Rhodes Pharmaceuticals L.P. (collectively, “Purdue“).

² For a full list of Purdue prescription opioids, visit PurduePharmaClaims.com.

SOURCE Prime Clerk the Court-Appointed Claims and Noticing Agent

BETHESDA, Maryland, June 3, 2020 /PRNewswire-HISPANIC PR WIRE/ — Researchers supported by the National Institutes of Health and the Bill & Melinda Gates Foundation will assess whether a single oral dose of the antibiotic azithromycin during labor reduces the risk of maternal and infant bacterial infection and death in seven low- and middle-income countries.

“We urgently need effective interventions to reduce the death toll of pregnancy-related infections worldwide,” said Diana W. Bianchi, M.D., NICHD Director. “This study allows us to test a low-cost intervention that has shown promise in a smaller study.”

The clinical trial is funded by NIH’s Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the Gates Foundation. The trial will be conducted by researchers in NICHD’s Global Network for Women’s and Children’s Health Research, or NICHD Global Network.

Maternal death from sepsis—a system-wide reaction to bacterial and other infections—is higher in many low- and middle-income countries, compared to wealthy countries. This higher death rate results from a combination of factors, including a longer time to diagnosis, lack of access to timely drug treatment and chronic malnourishment. Infection during pregnancy and in the weeks after birth account for roughly 10% of maternal deaths worldwide, according to the World Health Organization. Infection accounts for 16% of newborn deaths worldwide.

Azithromycin, an antibiotic effective against a broad range of bacteria, has been shown to protect against infection resulting from cesarean delivery. The drug is low-cost and can be kept at room temperature, which makes it suitable for parts of the world where refrigeration isn’t always available. An earlier study of more than 800 women in The Gambia found that administering azithromycin to pregnant women at the beginning of labor reduced maternal and infant infections, compared to a group that received a placebo. Azithromycin and other antibiotics are not effective against COVID-19 and other diseases caused by viruses.

The current study plans to enroll up to 34,000 women at NICHD Global Network sites in Bangladesh, the Democratic Republic of the Congo, Guatemala, India, Kenya, Pakistan and Zambia. Half of the women will receive a single 2-gram dose of oral azithromycin, and the other half will receive a placebo. The women and their infants will be monitored for fever and other signs of infection during their hospital stay and again at one week and six weeks after giving birth. The study will also include records of unscheduled visits to health facilities outside of the network sites.

“The NICHD Global Network provides the expertise and infrastructure needed to carry out this essential clinical trial,” said lead investigator Waldemar Carlo, M.D., of the Neonatology Division of the University of Alabama at Birmingham. “We anticipate that this study will provide important data to help us improve the standard of maternal care in low- and middle-income countries.”

The Foundation for the National Institutes of Health, a not-for-profit organization that manages alliances with public and private institutions in support of the NIH mission, provided funding for the study with a grant from the Gates Foundation.

Reference

Azithromycin-Prevention in Labor Use Study (A-PLUS). NICHD Global Network for Women’s and Children’s Health. https://clinicaltrials.gov/ct2/show/NCT03871491

###

About the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD): NICHD leads research and training to understand human development, improve reproductive health, enhance the lives of children and adolescents, and optimize abilities for all. For more information, visit http://www.nichd.nih.gov.

About the National Institutes of Health (NIH): NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov

SOURCE National Institutes of Health (NIH); Eunice Kennedy Shriver National Institute of Child Health and Human Development